impact factor, citescore
logo
In press
In Press
Recent issue
Recent issue
Recent Supplement
Recent supplement
archives
Archives
articles free
Free to view
Search
Search
 

Full Papers

 

Choice of the most appropriate biological disease-modifying anti-rheumatic drug for injection spacing: results from a multicentre observational study

1, 2, 3, 4, 5

 

  1. Matsuno Clinic for Rheumatic diseases, Kureha, Toyama city, Japan. info@toyama-ra.com
  2. Katayama Orthopaedic Rheumatology Clinic, Asahikawa, Japan.
  3. Matsubara Mayflower Hospital, Kato, Japan.
  4. Department of Clinical Research Support, Tokyo Metropolitan Center and Infectious Disease Center, Komagome Hospital, Tokyo, Japan.
  5. Matsubara Mayflower Hospital, Kato, Japan.

CER11880
2020 Vol.38, N°3
PI 0398, PF 0404
Full Papers

purchase article

PMID: 31287398 [PubMed]

Received: 07/11/2018
Accepted : 10/06/2019
In Press: 08/07/2019
Published: 26/05/2020

Abstract

OBJECTIVES:
To determine which biological disease-modifying anti-rheumatic drug (bDMARD) is most appropriate for spacing in patients with rheumatoid arthritis (RA) who have persistent stable symptoms.
METHODS:
In patients with sustained low disease activity (LDA) or better for ≥3 months who were treated with bDMARDs, the interval between bDMARD injections was extended 1.5 times, and treatment continuation rates at 104 weeks were calculated for each drug. Patients who discontinued therapy owing to adverse reactions and those who withdrew for reasons unrelated to the drugs were excluded. Whether patients could remain in LDA or better after injection spacing was investigated. The targeted drugs were an anti-tumour necrosis factor (TNF) inhibitor (golimumab [GOL]) and 2 non-TNF inhibitors (tocilizumab [TCZ] and abatacept [ABT]).
RESULTS:
The spacing evaluation included 57, 93, and 40 patients who received GOL subcutaneous injection (SC), TCZ (SC in 21 and drip intravenous injection [DIV] in 72), and ABT (SC in 12 and DIV in 22), respectively. At 104 weeks, the number of patients who discontinued therapy owing to adverse reactions did not significantly differ among the drugs. At 104 weeks, the treatment continuation rate was 0.71 for TCZ SC, 0.70 for GOL, 0.69 for TCZ DIV, 0.55 for ABT SC, and 0.50 for ABT DIV. The continuation rate for ABT was significantly lower than those for GOL and TCZ. No significant difference in continuation rates was observed between SC and DIV.
CONCLUSIONS:
When the injection interval was extended, GOL and TCZ were superior to ABT in terms of continuation rate.

Rheumatology Article